Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

Trial StartNEREUS™Positive

AI Analysis

Summary

Vanda Pharmaceuticals announced the initiation of the Thetis clinical trial evaluating NEREUS (tradipitant) for preventing vomiting in patients receiving GLP-1 receptor agonists.

Clinical Trial Data

Importance:4/10

Sentiment:

0.30

clinical trial initiationGLP-1 side effectstradipitantThetis study

Related Companies

$VNDA

Read the original article

Published by PR Newswire Biotech on April 8, 2026 8:44 PM

Read Original